News Releases

Date Title and Summary View
Jul 18, 2000
Johnson & Johnson 2000 Second Quarter EPS Rose 14.6% Sales Increased 7.7% Net Earnings Rose 14.3
Johnson & Johnson 2000 Second Quarter EPS Rose 14.6% Sales Increased 7.7% Net Earnings Rose 14.3 NEW BRUNSWICK, N.J., July 18 -- Johnson & Johnson (NYSE: JNJ) today announced record sales of $7.5 billion and record net earnings of $1.3 billion for the second quarter of 2000, increases of 7.7% and
Jun 25, 2000
Myths and Misconceptions Complicate the Choice of Vision Correction Options
Myths and Misconceptions Complicate the Choice of Vision Correction Options JACKSONVILLE, Fla., July 25 -- According to a recent Roper Starch survey of American adults, 67 percent currently wear some form of vision correction. Yet, making sense of the latest vision care information can prove
Jun 22, 2000
New ACUVUE® Brand TORIC Contact Lenses Emphasize Unique Dual Thin Stabilization Design
New ACUVUE ® Brand TORIC Contact Lenses Emphasize Unique Dual Thin Stabilization Design JACKSONVILLE, Fla., June 22 -- The VISTAKON ® Division of Johnson & Johnson Vision Care, Inc. announced today the availability of the ACUVUE ® Brand TORIC Contact Lens, featuring a breakthrough Dual Thin Zone
May 12, 2000
First OTC Ibuprofen Treatment for Migraine Headache Pain Hits Store Shelves; Motrin Migraine Pain from McNeil Consumer Healthcare Provides Aspirin-free, Caffeine-free Choice for Consumers
First OTC Ibuprofen Treatment for Migraine Headache Pain Hits Store Shelves; Motrin Migraine Pain from McNeil Consumer Healthcare Provides Aspirin-free, Caffeine-free Choice for Consumers FORT WASHINGTON, Pa.--May 1, 2000--McNeil Consumer Healthcare today announced the national introduction of
Apr 19, 2000
Johnson & Johnson Announces Dividend Increase of 14.3
Johnson & Johnson Announces Dividend Increase of 14.3 NEW BRUNSWICK, N.J., April 19 -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 14.3% increase in the quarterly dividend rate, from $0.28 per share to $0.32 per share.
Apr 18, 2000
Johnson & Johnson 2000 First Quarter EPS Rose 16.3% Sales Increased 8.6% Net Earnings Rose 15.5
Johnson & Johnson 2000 First Quarter EPS Rose 16.3% Sales Increased 8.6% Net Earnings Rose 15.5 NEW BRUNSWICK, N.J., April 18 -- Johnson & Johnson (NYSE: JNJ) today announced record sales of $7.3 billion and record net earnings of $1.3 billion for the first quarter of 2000, increases of 8.6% and
Apr 04, 2000
Cordis Enters Strategic Agreements with Guidant Corp. For Cardiovascular Devices and Therapies
Cordis Enters Strategic Agreements with Guidant Corp. For Cardiovascular Devices and Therapies NEW BRUNSWICK, N.J., April 4-- Cordis Corporation, a wholly owned unit of Johnson & Johnson (NYSE: JNJ), today reported it has entered into an agreement with Guidant Corporation (NYSE: GDT) (PCX: GDT)
Mar 29, 2000
Major Medical Products and Services Companies Establish Global Healthcare Exchange
Major Medical Products and Services Companies Establish Global Healthcare Exchange NEW YORK----March 29, 2000-- Exchange will make it faster, easier and less expensive for healthcare customers and companies to conduct business Johnson & Johnson, GE Medical Systems, Baxter International Inc., Abbott
Mar 14, 2000
Gamma 2: Major Clinical Trial Presented at ACC Cites Safety and Efficacy Of Gamma Radiation For Treating Reclogged Stents in Coronary Arteries
Gamma 2: Major Clinical Trial Presented at ACC Cites Safety and Efficacy Of Gamma Radiation For Treating Reclogged Stents in Coronary Arteries ANAHEIM, Calif., March 14 -- Preliminary six-month angiographic and nine-month clinical results of a newly completed landmark clinical trial using a
Mar 13, 2000
Arbitrator Issues Rulings Favorable to Johnson & Johnson In License Dispute with Amgen
Arbitrator Issues Rulings Favorable to Johnson & Johnson In License Dispute with Amgen NEW BRUNSWICK, N.J., March 13 -- The arbitrator presiding over Amgen's attempt to terminate Ortho Biotech's license to sell PROCRIT in the United States has denied motions for summary judgment by both parties,
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.